These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24770536)

  • 21. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
    Cohen D
    BMJ; 2015 Apr; 350():h1981. PubMed ID: 25869865
    [No Abstract]   [Full Text] [Related]  

  • 22. Avastin and Lucentis: a guide through the legal maze.
    Lock D
    BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
    [No Abstract]   [Full Text] [Related]  

  • 23. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 24. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 25. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New drugs for indications currently treated by off-label drugs: intravitreal dexamethasone and ranibizumab].
    Monzón Moreno A
    Farm Hosp; 2012; 36(2):57-9. PubMed ID: 22030162
    [No Abstract]   [Full Text] [Related]  

  • 29. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients.
    De Bats F; Grange JD; Cornut PL; Feldman A; Burillon C; Denis P; Kodjikian L
    J Fr Ophtalmol; 2012 Nov; 35(9):661-6. PubMed ID: 23040443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?].
    Waisbourd M; Leibovitch I; Loewenstein A; Yassur Y
    Harefuah; 2008 Jul; 147(7):605-6, 662. PubMed ID: 18814519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-label prescribing in macular degeneration.
    McCartney M
    BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravitreal ranibizumab and bevacizumab: a review of risk.
    Dafer RM; Schneck M; Friberg TR; Jay WM
    Semin Ophthalmol; 2007; 22(3):201-4. PubMed ID: 17763246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
    Schmucker C; Antes G; Lelgemann M
    Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
    [No Abstract]   [Full Text] [Related]  

  • 36. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM; Vecera KF; Barnes KN; Reski JW; Forinash AB
    Ann Pharmacother; 2012 Feb; 46(2):290-6. PubMed ID: 22274144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreous bevacizumab adult safety data: the evidence so far.
    Al-Qureshi S; Shaikh S
    Clin Exp Ophthalmol; 2012; 40(1):3-5. PubMed ID: 22304024
    [No Abstract]   [Full Text] [Related]  

  • 38. [Exsudative AMD: Regression analysis of transpupillary thermotherapy with and without intravitreal injection of triamcinolone, bevacizumab and ranibizumab].
    Weber U
    Klin Monbl Augenheilkd; 2010 Nov; 227(11):897-904. PubMed ID: 20640976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Avastin and Lucentis for macular degeneration].
    Nau JY
    Rev Med Suisse; 2012 Aug; 8(351):1636-7. PubMed ID: 22988719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.